AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
HBM rises from the ashes as a research partner for drug giants
The cash-strapped company disposed of a factory and an advanced drug pipeline to stay in business, and is now re-positioning itself as a supplier of biomedical services Key Takeaways: HBM…
Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
FAST NEWS: Henlius Lung Cancer Drug Gets ‘Orphan’ Status in Europe
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Thursday its self-developed small cell lung cancer drug Hansizhuang has been granted orphan drug status by the European Commission (EC).Looking up:…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
